Eligibility for vericiguat in a real‐world, contemporary heart failure population

Abstract Aims Vericiguat is a soluble guanylate cyclase stimulator and improves survival in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and an increased risk of decompensation. As real‐world data on how many patients could be eligible for vericiguat therapy derive from ou...

Descripció completa

Dades bibliogràfiques

Autors principals:	Giuseppe Vergaro, Alberto Aimo, Francesco Gentile, Giulia Elena Mandoli, Marta Focardi, Vincenzo Castiglione, Alberto Giannoni, Giorgia Panichella, Alessandra Fornaro, Erberto Carluccio, Riccardo Liga, Mattia Salatin, Claudio Passino, Massimo F. Piepoli, Matteo Cameli, Francesco Cappelli, Carlo Di Mario, Michele Emdin
Format:	Artigo
Idioma:	Inglês
Publicat:	Oxford University Press 2024-12-01
Col·lecció:	ESC Heart Failure
Matèries:	Vericiguat Heart failure Therapy Guidelines Population
Accés en línia:	https://doi.org/10.1002/ehf2.14767
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!